Forest CEO: Aptalis a `Compelling Opportunity'

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

Jan. 8 (Bloomberg) -- Brent Saunders, chief executive officer of Forest Laboratories Inc., talks about the company's agreement to acquire Aptalis Pharma for $2.9 billion in cash. Aptalis is a closely held company whose shareholders include investment firm TPG Capital. Saunders speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change